Assetmark Inc. Has $37,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Assetmark Inc. grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,153.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 188 shares of the medical research company’s stock after buying an additional 173 shares during the quarter. Assetmark Inc.’s holdings in Charles River Laboratories International were worth $37,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Boston Trust Walden Corp grew its stake in shares of Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after purchasing an additional 5,375 shares during the period. Natixis acquired a new position in shares of Charles River Laboratories International in the first quarter valued at approximately $1,058,000. Tidal Investments LLC boosted its position in shares of Charles River Laboratories International by 99.8% in the first quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock valued at $1,435,000 after acquiring an additional 2,646 shares during the period. Epoch Investment Partners Inc. grew its position in shares of Charles River Laboratories International by 2,733.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock worth $67,060,000 after purchasing an additional 238,766 shares in the last quarter. Finally, Quest Partners LLC lifted its position in shares of Charles River Laboratories International by 135,175.0% during the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock valued at $1,118,000 after acquiring an additional 5,407 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $187.50 on Tuesday. The stock has a market cap of $9.59 billion, a P/E ratio of 23.47, a P/E/G ratio of 4.84 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The company has a 50 day moving average of $195.24 and a 200 day moving average of $206.89. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the previous year, the company earned $2.72 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.19 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a share buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CRL shares. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday. Redburn Atlantic began coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Barclays lowered their target price on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Finally, Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $214.38.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).